Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A team of researchers identified a cell surface receptor, CXCR2, essential for hormone-resistant prostate cancer cells. They showed that targeting this receptor can halt tumor growth using a drug originally intended for lung diseases.
A clinical trial found that olaparib slowed or stopped tumour growth in men with advanced prostate cancer and BRCA mutations, with a median overall survival of 17.7 months. The study suggests that PARP inhibitors could become the first gene-targeted drug to be approved for prostate cancer.
A new study presents a novel MRI-guided procedure that effectively treats prostate cancer with minimal side effects. The technique, called TULSA, uses therapeutic ultrasound to destroy diseased prostate tissue while sparing healthy nerve tissue.
A University of Colorado Cancer Center study suggests two new approaches to treating bone metastases from prostate cancer: targeting different signaling pathways for lytic and blastic lesions. Both types of bone metastases show promise with anti-cancer immunotherapy, particularly those with high PD-L1 levels.
A new home urine test has shown to accurately diagnose aggressive prostate cancer and predict treatment needs up to five years earlier than standard clinical methods. The 'PUR' test looks at gene expression in urine samples and provides vital information about tumor aggressiveness.
A novel theranostic reagent has been developed to detect and treat metastatic prostate cancer, achieving high imaging accuracy. The reagent targets STEAP1 antigen, identifying lesions in patients with a significant number of positive results.
A new radiation therapy regimen combining lutetium-177 and actinium-225 has been shown to stabilize tumour growth and improve survival rates for patients with late-stage prostate cancer. The study demonstrated significant reductions in side effects, including dry mouth, compared to previous radionuclide therapies.
Men receiving care at multidisciplinary prostate cancer clinics are more likely to be informed about treatment options and receive evidence-based care, according to a new study. African American men also tend to opt for definitive therapy, challenging national trends.
Researchers at Intermountain Medical Center found that omega-3 fatty acids do not increase the risk of prostate cancer, contrary to earlier studies. High levels of omega-3s also showed a lower risk of adverse cardiovascular events and death in patients with severe coronary artery disease.
Researchers discover BRN4 overexpression drives neuroendocrine prostate cancer cell conversion in patients with recurrent cancer. Exosome inhibitors under study as potential treatment.
A large study of over 200,000 men found that high levels of 'free' testosterone and insulin-like growth factor-I (IGF-I) are associated with an increased risk of prostate cancer. The research suggests that these hormones could be modified to reduce prostate cancer risk, taking us a step closer to strategies for prevention.
The UCLA prostate cancer program has been awarded an $8.7 million SPORE grant to develop new approaches for improving diagnosis, prognosis, and treatment of prostate cancer. The grant will fund three translational research projects to find better ways to treat men with advanced stages of the disease.
A multi-centre registry trial is testing the use of a new PSMA tracer to detect early recurrence of prostate cancer. The trial provides valuable insights and has already shown promising results for patients like Wayne Smith, who was able to have a shorter round of hormone therapy.
A biomedical engineer at Worcester Polytechnic Institute is creating a new medical robot that uses photoacoustic imaging to detect and analyze three different indicators of prostate cancer. The system aims to be more accurate than current tests like ultrasounds and biopsies, while eliminating the need for radioactive contrast dye.
A comprehensive review of studies found a positive association between high dairy consumption and increased prostate cancer risk. In contrast, plant-based diets were associated with decreased risks of prostate cancer.
A study of over 13,000 cancer-free men found statin use was associated with a lower risk of developing prostate cancer. The association was strongest for aggressive tumors and only observed at high doses or long durations.
The study used the 18F-labelled PSMA-1007 radiotracer to detect recurrent and metastatic prostate cancer, which was not identified by conventional diagnostic imaging. The hospital aims to spread nuclear medicine that uses drugs labeled with α-emitting radionuclides for higher therapeutic effects.
A long-term cohort study of over 36,000 Japanese men found that consuming mushrooms on a regular basis reduces the risk of prostate cancer. Participants who ate mushrooms three or more times per week had a 17% lower risk compared to those who ate less frequently.
A study has identified a novel biomarker, KLK4-KLKP1 fusion gene, detectable in urine samples of patients with prostate cancer. This non-invasive method may replace traditional PSA tests, reducing unnecessary biopsies and improving diagnosis accuracy.
A new treatment approach for metastatic prostate cancer has shown promising results, delaying disease progression by more than double and potentially extending lives. The treatment targets genetic alterations that enable cancer cells to repair themselves, leading to significant extensions in time before the disease grows and spreads.
A recent study has shown that targeting faulty DNA repair mechanisms can slow the progression of advanced prostate cancer and improve survival rates. The PROfound trial demonstrated a significant delay in cancer progression with olaparib, compared to new hormonal agents, in patients with metastatic, pre-treated prostate cancer.
A national register study from Lund University found that fathers who underwent assisted reproduction, such as IVF and ICSI, had a 30-60% higher risk of developing prostate cancer compared to those who conceived naturally. The study also showed that men treated for infertility had a higher risk of prostate cancer at a young age.
A new analysis finds that long-term hormone therapy increases mortality risk for men with low PSA levels after prostate surgery. The study suggests that patients with high PSAs should continue to receive hormone therapy in addition to radiation, but those with low PSAs may be better off without it.
A randomized clinical trial found that high-dose radiation therapy can generate an immune system response similar to vaccination, sparking a systemic immune reaction against cancer. Patients treated with stereotactic ablative radiotherapy lived significantly longer without disease progression.
Researchers have discovered that certain molecules in semen, known as miRNAs, may serve as non-invasive biomarkers for prostate cancer. The study found that these molecules can provide reliable information to help diagnose and predict the progression of the disease.
Men who became fathers through assisted reproduction techniques have a higher risk of prostate cancer and early onset prostate cancer compared to those who conceived naturally. Early screening and long-term monitoring are advised for these men.
Researchers from the University of Bath screened over 20,000 molecules to find compounds that inhibit α-methylacyl-CoA racemase (AMACR) protein, increasing its levels in prostate cancer cells. This approach identified novel small-molecule inhibitors with potential therapeutic applications.
Researchers at George Washington University found a potential therapeutic target for prostate cancers with PTEN mutation by identifying the connection between PTEN and ARID4B genes. Suppressing ARID4B expression in cancer cells with PTEN mutation significantly inhibits cell growth and increases cell death.
Scientists at University of Bath have developed a new family of drugs that inhibit the AMACR protein, increasing effectiveness by 20-fold. The research provides promising avenues for treating prostate and other cancers.
A study found that men with the BRCA2 gene fault are almost twice as likely to be diagnosed with prostate cancer and develop more serious tumours. Regular PSA testing could help detect these cancers earlier.
The team aims to understand how genetics contributes to driving aggressive pathology in prostate cancer by combining pathology, computational modeling, and genomics. They plan to identify therapeutic options by testing combinations of genes in mouse models of the disease.
Researchers created a biosensor for detecting prostate cancer recurrence with high sensitivity and low cost. The device, like a home pregnancy test, provides immediate results and can help improve patient outcomes.
A new blood test detects early cancer cells in the bloodstream, predicting aggressive prostate cancer with high accuracy. Combining this test with the current PSA test reduces unnecessary biopsies and overtreatment of benign conditions.
A new study found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men. Regular mushroom intake was associated with an 8-17% lower risk of prostate cancer.
A large cohort study found that obesity is consistently associated with a greater burden of symptoms and experiences of distress among patients with breast or prostate cancer. Among patients with colon cancer, significant symptoms and distress were observed regardless of weight, suggesting alternative factors at play.
A new dual imaging approach combines transrectal ultrasound (TRUS) and photoacoustic imaging to detect anatomical features and molecular information of the prostate. This technology has shown promise in detecting prostate cancers with high accuracy, including distinguishing malignant regions in patients with advanced disease.
Researchers tested AuroLase Therapy, a treatment using gold-silica nanoshells, in 16 men with low- to intermediate-grade prostate cancer. The treatment was successful in 87.5 percent of lesions treated at one year of follow-up, preserving quality of life.
A cancer therapy invented at Rice University has shown promising results in clinical trials, destroying tumors without debilitating side effects. Thirteen of the first 15 prostate cancer patients treated with AuroLase Therapy showed no detectable signs of cancer a year after treatment.
Researchers from Bern, Switzerland have been awarded major grants by the US Department of Defense to study new treatments for prostate cancer and develop methods to preserve severed limbs. The projects aim to identify factors driving metastasis and improve survival rates in prostate cancer patients.
A large population-based study found that novel oral androgen signaling inhibitor therapies increase the risk of death in patients with pre-existing cardiovascular conditions. Patients with three or more heart conditions experienced a 50% increase in mortality, while enzalutamide was associated with lower hospitalization rates.
A study found that chaperone protein Hsp70 inhibits toxic protein aggregates in the androgen receptor, which causes Kennedy's disease and prostate cancer. Hsp70 may be useful as a therapeutic target to treat these conditions.
As people age, the prostate grows, leading to an increased risk for prostate cancer and benign prostatic hyperplasia. A new UCLA study found that older mice have more luminal progenitor cells, which can generate new prostate tissue, helping explain why the prostate tends to grow with age.
The study found that adjuvant radiotherapy improved disease-free period for patients with locally advanced prostate cancer, with 82% of patients in the treatment group remaining disease-free. However, the treatment did not significantly impact survival rates.
Researchers at UVA have identified Hullk, a non-coding RNA that regulates biological processes in cells. The discovery offers potential for targeting and stopping prostate cancer progression with fewer side effects.
Scientists at MD Anderson Cancer Center found that PRC1 regulates metastasis by suppressing the immune system, leading to tumor blood vessel growth. A novel PRC1 inhibitor showed efficacy as a single treatment and cooperated with immunotherapy to suppress metastasis.
A Penn study of over 150,000 men with prostate cancer found that hormone therapy increased the likelihood of developing Alzheimer's disease or dementia. The treatment was associated with a 14% increased risk of Alzheimer's and a 20% increased risk of dementia compared to patients who did not receive hormone therapy.
A study of 154,089 older men diagnosed with prostate cancer found that androgen deprivation therapy increased the likelihood of being diagnosed with Alzheimer disease or dementia. The therapy was associated with a higher risk over an average follow-up period of eight years.
Researchers identify DNA-PK as a master regulator of gene networks promoting aggressive prostate cancer behaviors. A clinical trial combining standard-of-care with a first-in-man DNA-PK inhibitor shows promising early results.
A new study from the University of Pennsylvania finds that proton therapy can be as effective and safe as traditional treatments when administered in higher doses over a shorter period. The research, which included 184 men with non-metastatic prostate cancer, showed low rates of serious gastrointestinal and urologic issues.
A new biomarker in urine helps detect aggressive prostate cancer, improving detection accuracy and reducing unnecessary treatments. The noninvasive test was found to accurately identify high-risk individuals and achieved similar accuracy as invasive tissue-based tests.
The study identified three ways in which the FOXA1 gene mutates to trigger prostate cancer: FAST, FURIOUS, and LOUD. Class 1 mutations cause rapid DNA traversal, class 2 mutations prevent normal FOXA1 from binding, and class 3 mutations create duplications of oncogenes. These alterations have different clinical implications for patients.
Researchers developed a urine test called 'PUR' that can diagnose aggressive prostate cancer and predict treatment needs up to five years earlier than standard methods. The test identified men who are up to eight times less likely to require treatment within five years of diagnosis.
A novel combination therapy using two targeted treatments has shown to maximize efficacy while reducing side effects in men with progressive prostate cancer. The study found that nearly 70 percent of patients saw a more than 50 percent reduction in PSA levels after the treatment.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
Inflammatory and immune-regulatory mechanisms were altered in animal models and prostate cancer tumor samples of WTC responders. These findings suggest that exposure to World Trade Center dust may contribute to chronic inflammation, which can drive prostate cancer progression.
A study by Mount Sinai researchers found that World Trade Center responders with prostate cancer exhibited chronic inflammation in their prostates, which may have contributed to their cancer. The researchers suggest that this link could lead to the development of anti-inflammatory therapies for similar cases.
Researchers at UCLA Health Sciences have developed a more effective method for detecting prostate cancer by combining biopsy strategies. The new approach, which includes MRI-guided biopsy, increased the rate of cancer detection to up to 33% compared to traditional methods.
A new study by University of Surrey researchers found that community pharmacy interventions significantly improved physical activity levels and reduced weight, BMI, and cholesterol in men with prostate cancer. These lifestyle changes also led to increased grip strength and better overall fitness.
A new study found that the protein CCN3 is a key factor promoting prostate cancer invasion of bone and predicting poor outcomes. High CCN3 expression correlated with shortened overall survival and bone metastases, while low-expression groups had better survival rates.
A prospective study found that higher levels of abdominal and thigh fat are associated with an increased risk of aggressive prostate cancer. Men with a lower BMI showed a stronger association between visceral fat and advanced prostate cancer. Lifestyle interventions, such as diet and exercise, may also reduce the risk of prostate cancer.